Month: October 2024

Since the FDA approval of the first lung cancer immunotherapy regimen in 2015 based on the CheckMate-017 and 057 studies, lung cancer immunotherapy has evolved significantly over the past decade, becoming the first-line standard of care for patients with driver mutation-negative non-small cell lung cancer (NSCLC). However, as evidence accumulates and clinical experience grows, some issues continue to stir debate. During the recent "2024 CSCO Lung Cancer Standardized Treatment Workshop," Oncology Frontier interviewed Dr. Meiqi Shi from Jiangsu Cancer Hospital to discuss key topics such as the choice of immunotherapy, treatment for brain metastases, immunotherapy rechallenge, and management of adverse events.

Liver cancer, often referred to as the “silent killer,” is frequently diagnosed at an advanced stage. Current screening methods such as alpha-fetoprotein (AFP) testing and ultrasound lack sufficient sensitivity and specificity. Therefore, there is an urgent need for more efficient, accurate, and cost-effective screening tools. At the 2024 ESMO conference, former President of the Korean Surgical Society and Professor at Inje University Haeundae Paik Hospital, Wang Hee-Jung, presented a novel method based on digital PCR detection of circulating tumor DNA methylation markers, demonstrating promising sensitivity and specificity results. Oncology Frontier invited Dr. Tian Yang from the Third Affiliated Hospital of Naval Medical University to provide insights on this study.

In clinical practice, several criteria are available for evaluating liver transplant candidates, such as the Milan Criteria, UCSF Criteria in the U.S., Ontario Criteria in Canada, and domestic standards like the Fudan Criteria and Hangzhou Criteria in China. Among these, the Milan Criteria are the most widely adopted. However, differences in survival outcomes based on these criteria suggest the need for refinement. At the recently held 2024 International Liver Cancer Association (ILCA) Conference, a study utilizing data from the United Network for Organ Sharing (UNOS) compared survival rates between patients evaluated under the Milan Criteria and the Ontario Criteria. Oncology Frontier invited Dr. Zilin Cui from Tianjin First Central Hospital to introduce and review the study.

At the 2024 Chinese Anti-Cancer Association (CACA) Integration of Esophageal Cancer Academic Conference, Oncology Frontier invited Dr. Xiaobing Chen, Secondary Professor/Chief Physician at the Department of Internal Medicine at Henan Cancer Hospital and Chair of the CACA Esophageal Tumor Integrated Rehabilitation Committee, to provide an in-depth analysis of early signs of esophageal cancer, screening methods, and innovative strategies for clinical application of immune checkpoint inhibitors.